An Adapted Neural-Fuzzy Inference System Model Using Preprocessed Balance Data to Improve the Predictive Accuracy of Warfarin Maintenance Dosing in Patients After Heart Valve Replacement

被引:10
作者
Gu, Zhi-Chun [1 ]
Huang, Shou-Rui [2 ]
Dong, Li [3 ]
Zhou, Qin [4 ]
Wang, Jing [5 ]
Fu, Bo [6 ]
Chen, Jin [2 ]
机构
[1] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Pharm, Shanghai, Peoples R China
[2] Sichuan Univ, West China Hosp, Dept Evidence Based Med & Clin Epidemiol, Chengdu, Peoples R China
[3] Sichuan Univ, West China Hosp, Dept Cardiovasc Surg, Chengdu, Peoples R China
[4] Chongqing Med Univ, Affiliated Hosp 2, Dept Nutr, Chongqing, Peoples R China
[5] Anhui Med Univ, Affiliated Hosp 4, Dept Career Dev Div, Hefei, Peoples R China
[6] Tianjin Cent Hosp, Dept Cardiovasc Surg, Tianjin, Peoples R China
基金
中国国家自然科学基金;
关键词
Heart valve disease; Warfarin; Dose prediction; Model; Machine learning; Neural network; HAN CHINESE PATIENTS; CLINICAL FACTORS; CYP2C9; ALGORITHM; VKORC1; PHARMACOGENETICS; POLYMORPHISMS; REQUIREMENTS; STRATEGIES; GENOTYPE;
D O I
10.1007/s10557-021-07191-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Tailoring warfarin use poses a challenge for physicians and pharmacists due to its narrow therapeutic window and substantial inter-individual variability. This study aimed to create an adapted neural-fuzzy inference system (ANFIS) model using preprocessed balance data to improve the predictive accuracy of warfarin maintenance dosing in Chinese patients undergoing heart valve replacement (HVR). Methods This retrospective study enrolled patients who underwent HVR between June 1, 2012, and June 1, 2016, from 35 centers in China. The primary outcomes were the mean difference between predicted warfarin dose by ANFIS models and actual dose and the models' predictive accuracy, including the ideal predicted percentage, the mean absolute error (MAE), and the mean squared error (MSE). The eligible cases were divided into training, internal validation, and external validation groups. We explored input variables by univariate analysis of a general linear model and created two ANFIS models using imbalanced and balanced training sets. We finally compared the primary outcomes between the imbalanced and balanced ANFIS models in both internal and external validation sets. Stratified analyses were conducted across warfarin doses (low, medium, and high doses). Results A total of 15,108 patients were included and grouped as follows: 12,086 in the imbalanced training set; 2820 in the balanced training set; 1511 in the internal validation set; and 1511 in the external validation set. Eight variables were explored as predictors related to warfarin maintenance doses, and imbalanced and balanced ANFIS models with multi-fuzzy rules were developed. The results showed a low mean difference between predicted and actual doses (< 0.3 mg/d for each model) and an accurate prediction property in both the imbalanced model (ideal prediction percentage, 74.39-78.16%; MAE, 0.37 mg/daily; MSE, 0.39 mg/daily) and the balanced model (ideal prediction percentage, 73.46-75.31%; MAE, 0.42 mg/daily; MSE, 0.43 mg/daily). Compared to the imbalanced model, the balanced model had a significantly higher prediction accuracy in the low-dose (14.46% vs. 3.01%; P < 0.001) and the high-dose warfarin groups (34.71% vs. 23.14%; P = 0.047). The results from the external validation cohort confirmed this finding. Conclusions The ANFIS model can accurately predict the warfarin maintenance dose in patients after HVR. Through data preprocessing, the balanced model contributed to improved prediction ability in the low- and high-dose warfarin groups.
引用
收藏
页码:879 / 889
页数:11
相关论文
共 37 条
  • [1] Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation
    Anderson, Jeffrey L.
    Horne, Benjamin D.
    Stevens, Scott M.
    Grove, Amanda S.
    Barton, Stephanie
    Nicholas, Zachery P.
    Kahn, Samera F. S.
    May, Heidi T.
    Samuelson, Kent M.
    Muhlestein, Joseph B.
    Carlquist, John F.
    [J]. CIRCULATION, 2007, 116 (22) : 2563 - 2570
  • [2] A Randomized and Clinical Effectiveness Trial Comparing Two Pharmacogenetic Algorithms and Standard Care for Individualizing Warfarin Dosing (CoumaGen-II)
    Anderson, Jeffrey L.
    Horne, Benjamin D.
    Stevens, Scott M.
    Woller, Scott C.
    Samuelson, Kent M.
    Mansfield, Justin W.
    Robinson, Michelle
    Barton, Stephanie
    Brunisholz, Kim
    Mower, Chrissa P.
    Huntinghouse, John A.
    Rollo, Jeffrey S.
    Siler, Dustin
    Bair, Tami L.
    Knight, Stacey
    Muhlestein, Joseph B.
    Carlquist, John F.
    [J]. CIRCULATION, 2012, 125 (16) : 1997 - +
  • [3] Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P4502C9 gene polymorphisms on warfarin dose requirements
    Aquilante, CL
    Langaee, TY
    Lopez, LM
    Yarandi, HN
    Tromberg, JS
    Mohuczy, D
    Gaston, KL
    Waddell, CD
    Chirico, MJ
    Johnson, JA
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (04) : 291 - 302
  • [4] CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement
    Cen, Han-Jing
    Zeng, Wu-Tao
    Leng, Xiu-Yu
    Huang, Min
    Chen, Xiao
    Li, Jia-Li
    Huang, Zhi-Ying
    Bi, Hui-Chang
    Wang, Xue-Ding
    He, Yan-Ling
    He, Fan
    Zhou, Rui-Na
    Zheng, Qi-Shan
    Zhao, Li-Zi
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 70 (02) : 234 - 240
  • [5] Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin
    Gage, B. F.
    Eby, C.
    Johnson, J. A.
    Deych, E.
    Rieder, M. J.
    Ridker, P. M.
    Milligan, P. E.
    Grice, G.
    Lenzini, P.
    Rettie, A. E.
    Aquilante, C. L.
    Grosso, L.
    Marsh, S.
    Langaee, T.
    Farnett, L. E.
    Voora, D.
    Veenstra, D. L.
    Glynn, R. J.
    Barrett, A.
    McLeod, H. L.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 84 (03) : 326 - 331
  • [6] Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin
    Gage, BF
    Eby, C
    Milligan, PE
    Banet, GA
    Duncan, JR
    McLeod, HL
    [J]. THROMBOSIS AND HAEMOSTASIS, 2004, 91 (01) : 87 - 94
  • [7] Groszek Barbara, 2015, Przegl Lek, V72, P468
  • [8] Learning from Imbalanced Data
    He, Haibo
    Garcia, Edwardo A.
    [J]. IEEE TRANSACTIONS ON KNOWLEDGE AND DATA ENGINEERING, 2009, 21 (09) : 1263 - 1284
  • [9] A Bloody Mess: An Unusual Case of Diffuse Alveolar Hemorrhage Because of Warfarin Overdose
    Heffler, Enrico
    Campisi, Raffaele
    Ferri, Sebastian
    Crimi, Nunzio
    [J]. AMERICAN JOURNAL OF THERAPEUTICS, 2016, 23 (05) : E1280 - E1283
  • [10] The influence of sequence variations in factor VII, γ-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement
    Herman, Darja
    Peternel, Polona
    Stegnar, Mojca
    Breskvar, Katja
    Dolzan, Vita
    [J]. THROMBOSIS AND HAEMOSTASIS, 2006, 95 (05) : 782 - 787